NR3C2 and diabetes mellitus: A retrospective cohort study including 602 PA patients found that PA patients treated with mineralocorticoid receptor antagonists (MRAs) had approximately two-fold higher risk for cardiovascular outcomes, diabetes mellitus (DM), atrial fibrillation, and death [8].